CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Delta-Fly Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Delta-Fly Pharma Inc
37-5, Nishikino, Miyajima, Kawauchi-cho
Phone: +81 886371055p:+81 886371055 TOKUSHIMA-SHI, TKS  771-0116  Japan Ticker: 45984598

Business Summary
Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20193/31/2019Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Representative Director KiyoshiEshima 69 12/1/2010 12/1/2010
Senior Managing Director, Representative Director KenzoIizuka 55 6/1/2017 2/1/2013
Executive Director YasuoMatsueda 58 6/1/2017 6/1/2017
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 11 (As of 3/31/2019)
Outstanding Shares: 4,504,568 (As of 9/30/2019)
Shareholders: 2,462
Stock Exchange: TYO


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, December 15, 2019